These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38967585)

  • 1. Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma.
    Chang YH; Yu CH; Lu MY; Jou ST; Lin CY; Lin KH; Chang HH; Ni YL; Chou SW; Ko KY; Lin DT; Hsu WM; Chen HY; Yang YL
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31176. PubMed ID: 38967585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of Tumor Mutational Burden in Neuroblastoma.
    Hwang WL; Wolfson RL; Niemierko A; Marcus KJ; DuBois SG; Haas-Kogan D
    J Natl Cancer Inst; 2019 Jul; 111(7):695-699. PubMed ID: 30307503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
    Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
    Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
    Depuydt P; Boeva V; Hocking TD; Cannoodt R; Ambros IM; Ambros PF; Asgharzadeh S; Attiyeh EF; Combaret V; Defferrari R; Fischer M; Hero B; Hogarty MD; Irwin MS; Koster J; Kreissman S; Ladenstein R; Lapouble E; Laureys G; London WB; Mazzocco K; Nakagawara A; Noguera R; Ohira M; Park JR; Pötschger U; Theissen J; Tonini GP; Valteau-Couanet D; Varesio L; Versteeg R; Speleman F; Maris JM; Schleiermacher G; De Preter K
    J Natl Cancer Inst; 2018 Oct; 110(10):1084-1093. PubMed ID: 29514301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
    Brady SW; Liu Y; Ma X; Gout AM; Hagiwara K; Zhou X; Wang J; Macias M; Chen X; Easton J; Mulder HL; Rusch M; Wang L; Nakitandwe J; Lei S; Davis EM; Naranjo A; Cheng C; Maris JM; Downing JR; Cheung NV; Hogarty MD; Dyer MA; Zhang J
    Nat Commun; 2020 Oct; 11(1):5183. PubMed ID: 33056981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
    Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients.
    Chang HH; Liu YL; Lu MY; Jou ST; Yang YL; Lin DT; Lin KH; Tzen KY; Yen RF; Lu CC; Liu CJ; Peng SS; Jeng YM; Huang SF; Lee H; Juan HF; Huang MC; Liao YF; Lee YL; Hsu WM
    Oncotarget; 2017 Jan; 8(3):4360-4372. PubMed ID: 27966455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
    Hishiki T; Matsumoto K; Ohira M; Kamijo T; Shichino H; Kuroda T; Yoneda A; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Kaneko T; Hara J; Kaneko M; Ikeda H; Tajiri T; Nakagawara A;
    Int J Clin Oncol; 2018 Oct; 23(5):965-973. PubMed ID: 29700636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.
    Yoo SY; Kim JS; Sung KW; Jeon TY; Choi JY; Moon SH; Son MH; Lee SH; Yoo KH; Koo HH
    Cancer; 2013 Feb; 119(3):656-64. PubMed ID: 22952047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1B alterations identify aggressive tumors in neuroblastoma.
    Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
    Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and Prognostic Impact of
    Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
    J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
    Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK
    Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor.
    Lee JW; Park SH; Kang HJ; Park KD; Shin HY; Ahn HS
    Cancer Res Treat; 2018 Apr; 50(2):495-505. PubMed ID: 28546523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.
    Moreno L; Guo D; Irwin MS; Berthold F; Hogarty M; Kamijo T; Morgenstern D; Pasqualini C; Ash S; Potschger U; Ladenstein R; Valteau-Couanet D; Cohn SL; Pearson ADJ; London WB
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28794. PubMed ID: 33205902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.